Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Other financing activities (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Other financing activities for 7 consecutive years, with -$315000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other financing activities fell 730.0% to -$315000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a 79.82% decrease, with the full-year FY2017 number at $14.3 million, changed 0.08% from a year prior.
  • Other financing activities was -$315000.0 for Q3 2025 at Gyre Therapeutics, down from $1.7 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.7 million in Q2 2025 to a low of -$315000.0 in Q3 2025.